期刊
TRANSLATIONAL LUNG CANCER RESEARCH
卷 10, 期 4, 页码 1594-1607出版社
AME PUBL CO
DOI: 10.21037/tlcr-20-1114
关键词
Malignant pleural mesothelioma (MPM); prognosis; programmed death ligand 1 (PD-L1); programmed cell death 1 (PD-1)
资金
- Medical Scientific Fund of the Mayor of the City of Vienna [17028]
- Croatian Science Foundation [IP-2014-09-4173]
- Austrian Science Fund [FWF I2872, FWF I3522, FWF I3977, I4677]
- Hungarian National Research, Development and Innovation Office [ANN128666]
- Bolyai Research Scholarship of the Hungarian Academy of Sciences
- New National Excellence Program of the Ministry for Innovation and Technology [UNKP-19-4, UNKP-20-3]
- Austrian Science Fund (FWF) [I4677] Funding Source: Austrian Science Fund (FWF)
The study demonstrated that high PD-L1 TC expression independently predicts worse overall survival in MPM patients, while there was no significant correlation between PD-L1 or PD-1 TILs expression and overall survival. Further studies are needed to investigate the value of PD-L1/PD-1 expression as a marker for treatment response in MPM patients receiving immunotherapy.
Background: Programmed cell death 1/programmed death ligand 1 (PD-1/PD-L1) immune-checkpoint blockade is a promising new therapeutic strategy in cancer. However, expression patterns and prognostic significance of PD-L1 and PD-1 are still controversial in human malignant pleural mesothelioma (MPM). Methods: Formalin-fixed paraffin-embedded (FFPE) tumor samples from 203 MPM patients receiving standard treatment without immunotherapy were collected from 5 European centers. PD-L1 and PD-1 expression of tumor cells (TCs) and tumor-infiltrating lymphocytes (TILs) were measured by immunohistochemistry and correlated with clinical parameters and long-term outcome. Results: High (>10%) PD-L1 TC and PD-1 TILs expressions were found in 18 (8%) and 39 (24%) patients, respectively. PD-L1 was rarely expressed by TILs [>= 1%, n=13 (8%); >10%, n=1]. No significant associations were found between the PD-L1 or PD-1 expression of TCs or TILs and clinicopathological parameters such as stage or histological subtype. Notably, patients with high (>10%) TC-specific PD-L1 expression exhibited significantly worse median overall survival (OS) (6.3 vs. 15.1 months of those with low TC PD-L1 expression; HR: 2.51, P<0.001). In multivariate cox regression analysis adjusted for clinical parameters, high TC PD-L1 expression (>10%) proved to be an independent negative prognostic factor for OS (HR: 2.486, P=0.005). There was no significant correlation between PD-L1 or PD-1 expression of TILs and OS. Conclusions: In this multicenter cohort study, we demonstrate that high (>10%) PD-L1 expression of TCs independently predicts worse OS in MPM. Further studies are warranted to investigate the value of PD-L1/PD-1 expression as a marker for treatment response in MPM patients receiving immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据